Equities

Shanghai Allist Pharmaceuticals Co Ltd

688578:SHH

Shanghai Allist Pharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)40.98
  • Today's Change-1.37 / -3.23%
  • Shares traded4.46m
  • 1 Year change+21.71%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,5102,0372,260
Total Receivables, Net29116249
Total Inventory633221
Prepaid expenses374938
Other current assets, total6.415.806.62
Total current assets2,9082,2862,375
Property, plant & equipment, net529544411
Goodwill, net------
Intangibles, net666867
Long term investments1,01551338
Note receivable - long term41198.31
Other long term assets(184)0228
Total assets4,3763,4423,130
LIABILITIES
Accounts payable534432
Accrued expenses1579045
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.431.664.72
Other current liabilities, total17811974
Total current liabilities390255156
Total long term debt0.390.300.68
Total debt1.821.965.39
Deferred income tax0.14----
Minority interest------
Other liabilities, total3.650.200.20
Total liabilities394255157
SHAREHOLDERS EQUITY
Common stock450450450
Additional paid-in capital3,1753,1003,031
Retained earnings (accumulated deficit)264(380)(511)
Treasury stock - common------
Unrealized gain (loss)94----
Other equity, total--183.25
Total equity3,9823,1872,973
Total liabilities & shareholders' equity4,3763,4423,130
Total common shares outstanding450450450
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.